ArticleNeuro-oncology advances
Patterns of radiological response to procarbazine and CCNU polychemotherapy in patients with oligodendroglioma.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To characterize the radiological response to procarbazine and CCNU (chloroethyl-cyclohexyl-nitrosourea) (PC) polychemotherapy in patients with oligodendroglioma. Methods: In this retrospective single-center cohort study, patients with Central Nervous System World Health Organization (CNS WHO) grade 2 or 3 oligodendroglioma treated with PC between 2003 and 2019 were included. Tumor characteristics were assessed on magnetic resonance imaging (MRI) and [ Results: Forty-six patients with a median follow-up of 118 months were identified. Median absolute T2 tumor volume was 52 cm³ (range 10-285) prior to PC and 29 cm³ (range 3-286) after. Median tumor volume decrease was -30% (range -96% to +113%). In treatment-naïve patients, median tumor volume decrease was -41% (range -92% to +14%) versus -7% (range -96% to +113%) in pretreated patients ( Conclusion: PC polychemotherapy induces substantial tumor volume reductions in subsets of patients with oligodendroglioma, particularly in treatment-naïve patients. The observations that circumscript oligodendrogliomas may be associated with earlier progression and that PC treatment may induce a shift toward a more diffuse phenotype require prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.